Available again · 02.09.2026
Supply shortage Austria: Mycobutin 150 mg - Kapseln
Affected country: Austria · Reported period: 16.02.2026 – 02.09.2026 · Active ingredient: RIFABUTIN
Notice context
A supply shortage has been recorded for Mycobutin 150 mg - Kapseln in Austria. The stated reason is “Regulatory changes”. The notice concerns the active ingredient RIFABUTIN and is identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Austria. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Mycobutin 150 mg - Kapseln is a supply signal concerning RIFABUTIN in Austria. The published reason “Regulatory changes” determines which data should be verified first.
For market or regulatory restrictions, authorisation and distribution status, pack version, destination country and the lawful sourcing route require separate assessment.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess product, authorisation, distribution and recipient status and the lawful case-specific sourcing route.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For market or status changes, the lawful product, distribution and recipient status for Mycobutin 150 mg - Kapseln must be clarified before storage.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using PZN 1304512, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 16.02.2026 to 02.09.2026 with the primary source and potential suppliers.
- Prioritise hospital demand, supply relevance and the escalation route with the accountable market participants.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Mycobutin 150 mg - Kapseln: